OPRX — OptimizeRx Cashflow Statement
0.000.00%
- $160.13m
- $179.56m
- $92.13m
- 80
- 43
- 98
- 86
Annual cashflow statement for OptimizeRx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -2.21 | 0.378 | -11.4 | -17.6 | -20.1 |
Depreciation | |||||
Non-Cash Items | 3.62 | 5.69 | 16.1 | 23.5 | 19.7 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -9.69 | -7.31 | 3.96 | -15.5 | 0.921 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -6.31 | 0.726 | 10.7 | -7.24 | 4.89 |
Capital Expenditures | -0.125 | -0.464 | -0.243 | -0.871 | -0.45 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Software Development Costs | |||||
Other Investing Cash Flow Items | 0 | -0.022 | -57.9 | -24.5 | — |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Cash from Investing Activities | -0.125 | -0.486 | -58.2 | -25.3 | -0.45 |
Financing Cash Flow Items | -4.39 | -1.61 | 0 | — | -0.911 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -1.9 | 73.9 | -19 | 28.2 | -4.91 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -8.34 | 74.2 | -66.5 | -4.36 | -0.472 |